- German SPD leaders vote to start exploratory talks with conservatives
- Lebanon interior minister signs law for May election: statement
- 'Congratulations': EU launches next phase of Brexit but warns of tough
- Brazil's Temer to leave hospital, return to Brasilia
- Poland gives government key election role, opposition sounds alarm
- Prince Harry and Meghan Markle to wed on May 19, 2018
- Britain's Prince Harry and Meghan Markle to marry on May 19
- Finland lets stores sell stronger drinks, health chiefs complain
- Multi-summit Macron burns energy in hunt for results
- Erdogan says Turkey seeking to annul Trump decision on Jerusalem at U.
- Russian ex-minister Ulyukayev jailed for eight years over $2 million b
- Mexico's Senate passes divisive security law, paving way for final app
- U.S. says concerned about Myanmar's silence over where Reuters journal
- 'Congratulations': EU launches next phase of Brexit
- Novo Nordisk wins EU panel's backing for key diabetes drug
- Pakistani top court rejects bid to bar opposition leader Imran Khan
- Aclaris's drug to treat common skin growth gets FDA nod
- Catalan election to return hung parliament: poll
- Aclaris's drug to treat common growth on skin gets FDA nod
- FDA allows Alnylam to restart hemophilia treatment trials
Australian watchdog takes GlaxoSmithKline, Novartis units to court
(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.
The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are “identically formulated”.
”We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.
ACCC’s concerns come as a price sampling conducted by it noted that supermarkets and pharmacies often sold Osteo Gel at a significant price premium to Emulgel.
The regulator is seeking declarations, injunctions, pecuniary penalties, and a publication order in relation to its allegations.
”The alleged conduct is particularly concerning, given the significant penalties handed down by the court against the makers of Nurofen for what we consider to be similar conduct,” Sims said.
In December last year, the Federal court of Australia upheld an appeal by the regulator against Reckitt Benckiser’s Australian unit for similar charges on its Nurofen Specific Pain products, imposing a A$6 million ($4.56 million) penalty.
($1 = 1.3160 Australian dollars)
Reporting by Susan Mathew in Bengaluru; Editing by Stephen Coates
Our Standards:The Thomson Reuters Trust Principles.